ASRS

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.

The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting.

Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 ASRS annual meeting.

The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

ICYMI: Dr. Clark breaks down the results of the PANORAMA Study

ICYMI: Dr. Singh shares the take-home message from his 2019 presentation

ICMYI: Dr. Wykoff discusses results from his ASRS presentation

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

This year’s ASRS PAT survey show subtle regional differences

 The ASRS Global Trends Survey finds differences in some treatment preferences

ICYMI: ASRS-developed program aims to support physicians with confidential comparisons

Ever wondered what it's like to compete in a Shark Tank-like competition? Find out!

Optical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.

Defining medicine and terms used can help move science forward

Researchers seeking fluid features, retinal integrity measures to test next step in image analysis and image interrogation in clinical trials.

David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.

Researchers find that targeted subretinal delivery of stem cell derived RPE to geographic atrophy is feasible 

Sunir J. Garg, MD, discusses hypersonic vitrector settings in surgery in the exhibition hall at ASRS 2018 in Vancouver.